Ochronosis: A Patient Guide
At a Glance
Ochronosis has two main forms: inherited alkaptonuria, which can deposit pigment in connective tissues and affect joints, heart valves, skin, and eyes, and exogenous ochronosis, usually linked to long-term skin-lightening products. Diagnosis and treatment depend on the cause.
IMPORTANT: This guide is educational. Do not diagnose yourself or start, stop, or change any treatment, medication, or diet based on these pages.
Ochronosis is a rare condition defined by the accumulation of a specific yellowish-ochre pigment in the body’s connective tissues. While the pigment itself is yellow, it appears as blue-black or gray-blue patches when viewed through the skin or in the cartilage of the ears and eyes. This visible change is the outward sign of a complex chemical process where substances that should be cleared by the body instead bond to collagen, the structural building block of our physical form [1][2].
Understanding your diagnosis begins with identifying which of two very different paths led to this pigment buildup. Confirmed AKU is managed differently from confirmed exogenous ochronosis, and you should not begin a restrictive diet or medication without the relevant specialist.
For some, the condition is Endogenous, caused by a rare genetic disorder called Alkaptonuria (AKU). In these cases, a missing enzyme allows a substance called homogentisic acid to build up in the blood, eventually depositing pigment into the joints, heart valves, and skin from the inside out. For others, the condition is Exogenous, a localized skin reaction triggered by external chemicals—most often the prolonged use of skin-lightening agents like hydroquinone [3][4].
The experience of living with ochronosis depends heavily on this distinction. Those with the genetic form often face a lifelong journey that begins with dark urine in infancy and progresses to unique joint and spinal challenges in adulthood. Those with the acquired form typically deal with stubborn, localized skin discoloration that does not affect the internal organs. Regardless of the cause, the path to a diagnosis is often long and confusing, frequently requiring the help of specialists to distinguish these rare signs from more common conditions [5][6].
Management of ochronosis focuses on stopping the progression of the pigment buildup. For the genetic form, this may involve a combination of prescription specialist medication to lower pigment levels and a carefully managed diet to protect the eyes and metabolic health. For the acquired form, management begins with immediately removing the triggering chemical and protecting the skin from further environmental stress. While the journey requires lifelong vigilance and a dedicated care team, modern medical advances and proactive monitoring provide a way to help protect your health and maintain your quality of life [7][8].
In this guide
6 chapters
Understanding Ochronosis: Genetic vs. Acquired Causes
Learn how endogenous and exogenous ochronosis differ, including causes, symptoms, urinary HGA testing, skin products, systemic risks, and next steps for care.
The Biology and Diagnosis of Ochronosis
Learn how ochronosis develops in alkaptonuria or after skin-cream use, and how urine HGA, HGD gene testing, biopsy, dermoscopy, and imaging help diagnose it.
Symptoms, Progression, and Warning Signs
Learn how ochronosis symptoms progress in alkaptonuria and exogenous ochronosis, and recognize emergency warning signs involving spine, heart, kidneys, and eyes.
Treatment Options and Daily Management
Learn how ochronosis is managed, from stopping hydroquinone and protecting skin to nitisinone, supervised diet, eye monitoring, and joint replacement options.
Long-term Monitoring and Care
Learn how alkaptonuria (AKU) monitoring supports nitisinone safety, including fasting tyrosine tests, slit-lamp exams, heart checks, and stone surveillance.
Building Your Care Team
Learn how to build an ochronosis care team, prepare for specialist visits, coordinate AKU or exogenous ochronosis care, and improve communication with doctors.
Common questions in this guide
What are the two main forms of ochronosis?
How do doctors determine whether I have ochronosis?
Can dark urine be an early sign of inherited ochronosis?
Can long-term use of hydroquinone cause ochronosis?
How is ochronosis treated?
Which specialists may be involved in ochronosis care?
Get notified when new evidence is published on ochronosis disorder.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (8)
- 1
A Mimic of Ankylosing Spondylitis, Ochronosis: Case Report and Review of the Literature.
Chu P, Cuellar MC, Bracken SJ, Tarrant TK
Current allergy and asthma reports 2021; (21(3)):19 doi:10.1007/s11882-021-01002-1.
PMID: 33666743 - 2
Alkaptonuria.
Bernardini G, Braconi D, Zatkova A, et al.
Nature reviews. Disease primers 2024; (10(1)):16 doi:10.1038/s41572-024-00498-x.
PMID: 38453957 - 3
Exogenous Ochronosis (EO): Skin lightening cream causing rare caviar-like lesion with banana-like pigments; review of literature and histological comparison with endogenous counterpart.
Qorbani A, Mubasher A, Sarantopoulos GP, et al.
Autopsy & case reports 2020; (10(4)):e2020197 doi:10.4322/acr.2020.197.
PMID: 33344320 - 4
Alkaptonuria in Turkey: Clinical and molecular characteristics of 66 patients.
Kisa PT, Gunduz M, Dorum S, et al.
European journal of medical genetics 2021; (64(5)):104197 doi:10.1016/j.ejmg.2021.104197.
PMID: 33746036 - 5
A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care.
Rudebeck M, Scott C, Sireau N, Ranganath L
JIMD reports 2020; (53(1)):71-79 doi:10.1002/jmd2.12101.
PMID: 32395411 - 6
Exogenous ochronosis associated with hydroquinone: a systematic review.
Ishack S, Lipner SR
International journal of dermatology 2022; (61(6)):675-684 doi:10.1111/ijd.15878.
PMID: 34486734 - 7
Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.
Ranganath LR, Psarelli EE, Arnoux JB, et al.
The lancet. Diabetes & endocrinology 2020; (8(9)):762-772 doi:10.1016/S2213-8587(20)30228-X.
PMID: 32822600 - 8
Clinical and Dermoscopic Characteristics of Facial Hyperpigmentation Disorders in Skin of Color.
Mansilla-Polo M, Díaz-Gómez CJ, Morgado-Carrasco D
Actas dermo-sifiliograficas 2026; (117(7)):104637 doi:10.1016/j.ad.2026.104637.
PMID: 41865981
This guide explains the different causes and management approaches for ochronosis for informational purposes only and does not replace medical advice. Do not start, stop, or change medication, diet, or skin products without guidance from the appropriate specialist.